Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Clinical trial NCT06302621 · RECRUITING

Trial details

NCT number: NCT06302621
Sponsor: Massachusetts General Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor Unresectable Solid Tumor Metastatic Solid Tumor Cholangiocarcinoma

Start date: 2024-04-17
Primary completion: 2027-12-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.